Healthcare entity
All 1 tracked stories fall under one category: regulation. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window.
Last mentioned: Jul 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 4 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. HIV+Hepatitis Policy Institute appears in 1 tracked Healthcare story from July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HIV+Hepatitis Policy Institute. Shared-story counts are live from our verified record — not editorial picks.
Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care.
HIV+Hepatitis Policy Institute is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
